全球前列腺癌治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計攝護腺癌治療市場將從 2025 年的 200.2 億美元成長到 2034 年的 447.9 億美元，2026 年至 2034 年的複合年成長率為 9.36%。

由於全球前列腺癌發生率不斷上升，全球前列腺癌治療市場正經歷顯著成長。人口老化和診斷篩檢的進步推動了治療率的提高。荷爾蒙療法、化療和標靶治療的進步正在促進市場擴張。人們對早期檢測意識的提高也進一步支撐了市場需求。

成長要素包括新型免疫療法和精準醫療方法的開發。生技和製藥公司對研發的投入正在加速創新。發展中地區醫療保健服務的普及也促進了治療方法的推廣。此外，政府的支持措施和癌症防治宣傳活動也為穩定成長做出了貢獻。

前景依然樂觀，這得益於正在進行的臨床試驗中引入的先進治療方案。聯合治療和個人化治療策略將改善患者的治療效果。全球醫療保健支出的成長預計將支撐市場的持續擴張。在醫療創新的驅動下，前列腺癌藥物市場預計將繼續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球前列腺癌治療市場：依療法分類

• 市場分析、洞察與預測
• 荷爾蒙療法
• 化療
• 免疫療法
• 標靶治療
• 其他

第5章 全球前列腺癌治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 雄性激素受體抑制劑
• GnRH受體拮抗劑
• PARP抑制劑
• 免疫查核點抑制劑
• 其他

第6章：全球前列腺癌治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第7章 全球前列腺癌治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球前列腺癌治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Dendreon Pharmaceuticals LLC
  • Exelixis, Inc
  • Ferring BV
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Sumitomo Pharma AmericaInc
  • Takeda Pharmaceutical Company Limited
  • Tolmar Inc

The Prostate Cancer Therapeutics Market size is expected to reach USD 44.79 Billion in 2034 from USD 20.02 Billion (2025) growing at a CAGR of 9.36% during 2026-2034.

The Global Prostate Cancer Therapeutics market has experienced notable growth due to increasing incidence of prostate cancer worldwide. Aging populations and improved diagnostic screening have contributed to rising treatment rates. Pharmaceutical advancements in hormonal therapy, chemotherapy, and targeted treatments have strengthened market expansion. Growing awareness about early detection further supports demand.

Growth drivers include development of novel immunotherapies and precision medicine approaches. Research investments by biotechnology and pharmaceutical companies accelerate innovation. Expanding healthcare access in developing regions also enhances treatment availability. Additionally, supportive government initiatives and cancer awareness campaigns contribute to steady growth.

Future prospects remain promising as ongoing clinical trials introduce advanced therapeutic options. Combination therapies and personalized treatment strategies will improve patient outcomes. Rising healthcare expenditure globally is expected to support sustained market expansion. The prostate cancer therapeutics market is poised for continued development driven by medical innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy

• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Other

By Drug Class

• Androgen receptor inhibitors
• GnRH Receptor Antagonist
• PARP Inhibitor
• Immune Checkpoint Inhibitors
• Other

By Route Of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Astellas Pharma Inc, AstraZeneca Plc, Bayer AG, Dendreon Pharmaceuticals LLC, Exelixis, Inc, Ferring BV, GlaxoSmithKline Plc, Ipsen Pharma, Johnson Johnson, Novartis AG, Pfizer Inc, Sanofi SA, Sumitomo Pharma America, Inc, Takeda Pharmaceutical Company Limited, Tolmar Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy
• 4.2. Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Androgen receptor inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. GnRH Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. PARP Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Immune Checkpoint Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapy
  • 8.2.2 By Drug Class
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapy
  • 8.3.2 By Drug Class
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapy
  • 8.4.2 By Drug Class
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapy
  • 8.5.2 By Drug Class
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapy
  • 8.6.2 By Drug Class
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PROSTATE CANCER THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Astellas Pharma Inc
  • 10.2.2 AstraZeneca Plc
  • 10.2.3 Bayer AG
  • 10.2.4 Dendreon Pharmaceuticals LLC
  • 10.2.5 Exelixis, Inc
  • 10.2.6 Ferring B.V
  • 10.2.7 GlaxoSmithKline Plc
  • 10.2.8 Ipsen Pharma
  • 10.2.9 Johnson & Johnson
  • 10.2.10 Novartis AG
  • 10.2.11 Pfizer Inc
  • 10.2.12 Sanofi S.A
  • 10.2.13 Sumitomo Pharma AmericaInc
  • 10.2.14 Takeda Pharmaceutical Company Limited
  • 10.2.15 Tolmar Inc